Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.
暂无分享,去创建一个
Artem Cherkasov | Eric Leblanc | Kate Frewin | R. Young | P. Rennie | F. Ban | Kriti Singh | A. Cherkasov | N. Lack | Peter Axerio-Cilies | Fuqiang Ban | P. Axerio-Cilies | Ravi Shashi Nayana Munuganti | Christophe Labriere | Kriti Singh | Mohamed D. H. Hassona | Nathan A. Lack | Huifang Li | Emma Tomlinson Guns | Robert Young | Paul S. Rennie | Huifang Li | E. Leblanc | Kate Frewin | R. Munuganti | M. Hassona | Christophe Labrière | E. T. Tomlinson Guns | Ravi Shashi Nayana Munuganti | Mohamed D H Hassona | Paul S Rennie | Ravi Shashi Nayana Munuganti
[1] C S Song,et al. Regulation of androgen action. , 1999, Vitamins and hormones.
[2] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[3] A. Parent,et al. Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors. , 2009, ACS chemical biology.
[4] S. Arya,et al. The LNCaP cell line--a new model for studies on human prostatic carcinoma. , 1980, Progress in clinical and biological research.
[5] R. Fletterick,et al. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells , 2011, Proceedings of the National Academy of Sciences.
[6] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[7] J. Dalton,et al. Chemistry and Structural Biology of Androgen Receptor , 2005 .
[8] Ryan G. Coleman,et al. ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..
[9] L. Mayr,et al. Evaluation of two novel tag-based labelling technologies for site-specific modification of proteins. , 2006, International journal of biological macromolecules.
[10] Michelle R. Arkin,et al. Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.
[11] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[12] H. Scher,et al. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. , 2009, The Lancet. Oncology.
[13] N. Dawson,et al. Emerging therapies in castrate-resistant prostate cancer , 2009, Current opinion in oncology.
[14] P. Carroll,et al. 20-year outcomes following conservative management of clinically localized prostate cancer , 2005 .
[15] Peyman Tavassoli,et al. Rapid, non‐destructive, cell‐based screening assays for agents that modulate growth, death, and androgen receptor activation in prostate cancer cells , 2007, The Prostate.
[16] Michelle R. Arkin,et al. Binding of small molecules to an adaptive protein–protein interface , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[17] M. Gleave,et al. Intermittent androgen suppression for prostate cancer: rationale and clinical experience , 1998, Prostate Cancer and Prostatic Diseases.
[18] M. Gottesman,et al. Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.
[19] Randy J. Read,et al. Acta Crystallographica Section D Biological , 2003 .
[20] Artem Cherkasov,et al. Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening. , 2011, Journal of medicinal chemistry.
[21] G. Bubley,et al. Biology of prostate-specific antigen. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Solène Grosdidier,et al. Allosteric conversation in the androgen receptor ligand-binding domain surfaces. , 2012, Molecular endocrinology.
[23] Phuong Nguyen,et al. A surface on the androgen receptor that allosterically regulates coactivator binding , 2007, Proceedings of the National Academy of Sciences.
[24] H. Scher,et al. ARN-509: a novel antiandrogen for prostate cancer treatment. , 2012, Cancer research.
[25] Artem Cherkasov,et al. Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening. , 2011, Journal of medicinal chemistry.
[26] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[27] P. Kantoff,et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] H. Scher,et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.
[29] D. Horsfall,et al. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. , 1994, Cancer research.
[30] R. Guy,et al. Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription. , 2009, ACS chemical biology.
[31] I. Tannock,et al. Drug resistance in metastatic castration-resistant prostate cancer , 2011, Nature Reviews Clinical Oncology.
[32] Y. Oshika,et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.
[33] Mary J. Meegan,et al. “True” Antiandrogens—Selective Non-Ligand-Binding Pocket Disruptors of Androgen Receptor–Coactivator Interactions: Novel Tools for Prostate Cancer , 2012, Journal of medicinal chemistry.
[34] B. Furr,et al. The development of Casodex (bicalutamide): preclinical studies. , 1996, European urology.